Tagged with Opinion

Opinion Meghann Chilcott, chief technology/marketing officer at Benzer Pharmacy provides insights for expanding point-of-care (POC) testing services in the US retail environment, and opportunities for improving patient outcomes and customer satisfaction in the process.   POC testing makes it possible for patients to receive the treatment or the advice they need…

Opinion In the light of several recent regulatory updates to Canada’s cannabis laws, lawyer Jean-Raphaël Champagne examines the potential for cannabis to be legalised for use in cosmetic products in Canada.   One thing that Bill C-51 did not change was the relationship between cannabis substances and cosmetic products in Canada…

Lithuania Ruta Pumputiene examines recent regulatory reform in Lithuania, as the Baltic nation attempts to introduce a holistic HTA mechanism for the evaluation of what to include on the country’s reimbursable medicines list.   It is not yet clear whether the new procedure will complicate and damage Lithuanian patients’ access to…

Mexico Cristobal Thompson of the AMIIF examines the steps forward that Mexican pharma has made in countering corruption, the areas in which urgent improvement is still needed, and outlines the three key reasons why fighting corrupt practices is so important.   The pharmaceutical industry must act according to value-based codes, building…

Portugal Joana Silveira Botelho of Cuatrecasas argues for the need for an EU-wide regulatory update on the advertising of pharmaceutical products online, given current rules do not take into account the spread and influence of social media today.   Today’s internet is so much more than a company’s website It is…

Opinion Tom Achoki of Mass Sciences explores the possibilities that better access to high-quality real-world data will create for accelerating novel drug discovery and ultimately improving patient outcomes.   Proactive decision makers within the biopharmaceutical industry need to find innovative ways to bridge the existing RWD gaps within their organization The…

Germany Peter Homberg of Dentons Germany examines the regulatory status quo around the free sale of products containing cannabidiol (CBD) across Europe. Although deregulation efforts are underway, Homberg argues that the trade in these products is not as free and unregulated as it may initially seem.   CBD products that are…

Opinion The Foundations for Evidence-Based Policy-Making Act, recently signed into law in the USA, stands to make government data more accessible; thereby allowing researchers, statisticians and others inside and outside of government to make better, and evidenced-based, policy decisions. Carla Smith outlines the scope of the Act and its potential implications…

Cannabis OPINION: Keith Wolsko and Danielle Moore of cannabis industry recruitment specialists Simply Kind Solutions highlight the seismic recent growth of the USA’s burgeoning cannabis industry and the kinds of profiles that the industry is looking for.   We are witnessing the birth of the next great American industry. So, you…

AI GSK’s Richard Saynor outlines the ways in which an increased embrace of technologies which utilise artificial intelligence can help improve health literacy and therefore patient outcomes.   In healthcare, AI has the potential to improve drug discovery, development and manufacturing, and enhance interactions with customers, doctors and patients As a…

Israel Saul Kaye of iCAN and CannaTech outlines a compelling case for Israel to be considered one of the world’s leading hostpots for medical cannabis; drawing on its R&D history, specific population needs, climate, advanced agricultural methods, and the willingness of the Israeli state to embrace what is still an emerging…

WHO Brendan Shaw outlines how a new approach to the WHO’s Essential Medicines List is needed to ensure both the patients of today and of the future can access the medicines they need.   For pharmaceutical companies, listing on the EML can be a double-edged sword. More than 40 years after its…